Company news

Optimi Health Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

October 26, 2026

Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia

October 20, 2026

Optimi Health to Present at the ThinkEquity Conference

October 7, 2026

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

September 16, 2026

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026

Optimi Health Establishes Discretionary Equity Facility

August 14, 2026

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

June 29, 2026

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

June 16, 2026

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

June 10, 2026

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

June 8, 2026

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

June 2, 2026

Optimi Health (OPTH) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update

May 29, 2026

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

May 29, 2026

Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)

May 27, 2026

Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date

May 26, 2026

Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering

May 21, 2026

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

May 20, 2026

Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing

April 23, 2026

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

March 16, 2026

Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia

February 26, 2026

Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression

February 19, 2026

Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics

February 17, 2026

Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme

February 9, 2026

Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules

January 26, 2026

Early Warning Press Release in Accordance with National Instrument 62-103

January 21, 2026

Optimi Health Announces Equity Incentive Grants and Corporate Update

January 16, 2026

Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026

January 14, 2026

Optimi Health Announces Appointment of New Director

December 18, 2025

Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD

November 26, 2025

Optimi Health Provides Corporate Update

October 21, 2025

Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program

October 6, 2025

Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering

September 8, 2025

Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression

September 3, 2025

Optimi Health Announces $3.45 Million Convertible Financing and Extension of Secured Term Loan

July 18, 2025

Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy

May 8, 2025

Optimi Health Obtains U.S. FDA Drug Establishment Registration

May 5, 2025

OPTEC Signs Amicable Settlement with Weshield & Collaberation of PPE Sales Agreement

February 3, 2022

This Week on MoneyTV with Donald Baillargeon, 9/17

September 17, 2021

This Week on MoneyTV with Donald Baillargeon, 8/6

August 6, 2021

This Week on MoneyTV with Donald Baillargeon, 7/16

July 16, 2021

This week on MoneyTV with Donald Baillargeon, 6/18

June 18, 2021

This Week on MoneyTV with Donald Baillargeon, 5/21

May 21, 2021

Vinco Ventures, Inc. announces deal with OPTEC International, Inc. and OPTEC Brand Ambassador Dr. Drew Pinsky

December 3, 2020

Stock Day Media OPTEC International "OPTI" CEO Interview Podcast Monday November 16th, 2020

November 16, 2020

OPTEC International, Inc. Discusses the Future of PPE Products with The Stock Day Podcast

October 7, 2020

This Week on MoneyTV with Donald Baillargeon, 8/14

August 14, 2020

Decks